ATXN3 and Machado-Joseph disease: Our study shows that administration of the AChE inhibitor neostigmine is beneficial in treating the locomotion defective phenotype of a SCA3/MJD model ofC. elegansand highlights the potential contribution of AChE enzymes to mutant ataxin-3-mediated toxicity.